Ann: Kazia Annual Report to shareholders, page-19

yes they will not take it through commercialisation he said that a heap of times that’s where others get it wrong trying to do things outside your core ability...

better to let a commercialisation company that’s very successful and already has the distribution and marketing networks in place.... it will be way quicker as well. You switch it on Friday reps show doctors from Monday etc.

if we sell the PRV we have funds to pull Paxalisib through more partner trials and do a phase 2 with Cantrixil and onboard compound 3.

though I too note that Cantrixil has not been the focus of this report - it may be more once it to is in phase 2 trials.

whats number 3 going to be ???